- Status:
- Grey - after consultant/specialist initiation, Red, Green
- Decision Date:
- None
Comments
GREEN:
GREY after consultant/specialist initiation:
- MR oral preparation. After consultant gastroenterologist and colorectal surgeon initiation. Long term maintenance with low dose (off-label) may be required in exceptional circumstances e.g., autoimmune hepatitis, microscopic colitis. (Decision date - January 2017).
RED:
- NICE TA708: Orodispersible tablet (Jorveza) for inducing remission of eosinophilic oesophagitis. Indicated for the treatment of eosinophilic oesophagitis in adults for 6 weeks. Continue for up to 12 weeks if inadequate response. (Decision date - April 2019).
- NICE TA937: for treating primary IgA nephropathy (Kinpeygo). (Decision date - January 2024)
Inhaled budesonide should no longer be considered as a treatment for individuals with COVID-19 infection other than within the context of a clinical trial. People already using budesonide for conditions other than COVID-19 should continue treatment if they test positive for COVID-19. See NICE NG191 Covid-19 rapid guideline: managing COVID-19 (updated Dec 2021).
search again